| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.02. | Tectonic Therapeutic, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 6 | SEC Filings | ||
| 26.02. | Tectonic Therapeutic GAAP EPS of -$1.03 beats by $0.08 | 1 | Seeking Alpha | ||
| 26.02. | Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | 1.552 | GlobeNewswire (Europe) | Announced positive topline results from TX45 Phase 1b acute hemodynamic clinical trial in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction ("PH-HFrEF")... ► Artikel lesen | |
| 26.02. | Tectonic Therapeutic, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 25.02. | Leerink cuts Tectonic Therapeutics stock price target on TX45 outlook | 1 | Investing.com | ||
| TECTONIC THERAPEUTIC Aktie jetzt für 0€ handeln | |||||
| 24.02. | Tectonic Therapeutic, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.02. | Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board | 199 | GlobeNewswire (Europe) | WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic... ► Artikel lesen | |
| 11.02. | Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026 | 2 | GlobeNewswire (USA) | ||
| 10.02. | Morning Market Movers: Abpro, Tectonic Therapeutic, Upwork, Ichor Holdings See Big Swings | 486 | AFX News | AKRON (dpa-AFX) - At 6:30 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 07.11.25 | Tectonic Therapeutic GAAP EPS of -$1.02 beats by $0.05 | 3 | Seeking Alpha | ||
| 06.11.25 | Tectonic Therapeutic, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.10.25 | Tectonic Therapeutic Surges 12% On Positive Phase 1b Topline Data For TX45 | 3 | RTTNews | ||
| 30.10.25 | Positive Studiendaten: Oppenheimer sieht bei Tectonic Therapeutics 330 % Kurspotenzial | 3 | Investing.com Deutsch | ||
| 30.10.25 | Tectonic Therapeutics stock maintains Outperform rating at Oppenheimer | 6 | Investing.com | ||
| 30.10.25 | TECX, GKOS, GH, ALGN, NMRA Surge After Hours On Clinical Data And Earnings | 670 | AFX News | WASHINGTON (dpa-AFX) - Several healthcare and life sciences names posted notable gains in after-hours trading, driven by clinical updates, earnings releases, and in some cases, unexplained momentum.Tectonic... ► Artikel lesen | |
| 29.10.25 | Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF | 233 | GlobeNewswire (Europe) | TX45 improved both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction ("PH-HFrEF")TX45 was well tolerated... ► Artikel lesen | |
| 17.05.25 | Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025 | 567 | GlobeNewswire (Europe) | Data confirmed TX45's tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,45 | -0,63 % | BioNTech vs. Bioxyne: Wenn Forschungs-Riesen pausieren und Small Caps die Prognosen anheben | ||
| EVOTEC | 4,526 | -3,21 % | Evotec Aktie: 2 Euro oder 6 Euro - wohin geht es für die Biotech-Aktie? | Nach dem Absturz der Evotec Aktie an die 4-Euro-Marke läuft bei dem Biotech-Titel ein erneuter Versuch einer Bodenbildung. Die zentrale charttechnische Unterstützung hat sich diesmal im Kern bei 3,995/4... ► Artikel lesen | |
| BB BIOTECH | 48,250 | +0,10 % | Dividenden als Portfolio-Anker: Alte Bekannte Sanofi und BB Biotech - Geheimtipp RE Royalties | In einem Marktumfeld, das von strukturellen Umbrüchen geprägt ist, rückt die Stabilität des Portfolios in den Fokus. Analysten von J.P. Morgan betonen, dass der Schutz von Buchgewinnen der vergangenen... ► Artikel lesen | |
| MEDIGENE | 0,026 | -17,20 % | Medigene: Zurückziehung - 18.11.2025 | ||
| QIAGEN | 35,030 | -1,14 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| MODERNA | 43,500 | -2,53 % | Moderna, Inc.: Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 | CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010... ► Artikel lesen | |
| PAION | 0,051 | -19,84 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WURDE STATTGEGEBEN | Dem Mistrade-Antrag wurde stattgegeben. Folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wurden aufgehoben:ISIN Datum Zeit Volumen PreisDE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| VALNEVA | 2,561 | -5,85 % | Valneva unter massivem Druck: Warum Insider bereits still und leise verkaufen - Was Sie jetzt noch wissen müssen | ||
| AMGEN | 306,25 | +2,15 % | Amgen: Phase 3 Trial Of TEPEZZA Meets Primary And Key Secondary Endpoints | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced positive topline results from a Phase 3 trial of TEPEZZA administered by subcutaneous injection via an on-body injector in participants with... ► Artikel lesen | |
| EPIGENOMICS | 0,925 | 0,00 % | PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Epigenomics... ► Artikel lesen | |
| NOVAVAX | 7,290 | +0,97 % | Activist investor revives campaign to overhaul Novavax board | ||
| STRYKER | 289,00 | -0,82 % | Outset Medical adds former Stryker leader as new EVP of commercial | ||
| BIOGEN | 151,28 | -1,89 % | Weekly Buzz: ARS Pharmaceuticals Gains FDA Nod; Novo Nordisk received FDA approval for Awiqli; EU Expands Kerendia Label; Eli Lilly Acquires Centessa Pharmaceuticals; Biogen Snaps Up Apellis Pharmaceuticals | BASEL (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S., EU, and China, acquisitions, a few key trial goal misses and positive clinical trial data readouts... ► Artikel lesen | |
| BIOFRONTERA | 2,610 | +1,95 % | BIOFRONTERA AG im Abwärtsmodus - ruhige Einordnung | ||
| HEIDELBERG PHARMA | 2,830 | +1,43 % | EQS-News: Heidelberg Pharma AG: Heidelberg Pharma präsentiert Ergebnisse ihrer proprietären ADC-Technologieplattform auf der AACR-Jahrestagung 2026 | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Wissenschaftl. Publikation
Heidelberg Pharma präsentiert Ergebnisse ihrer proprietären ADC-Technologieplattform auf der AACR-Jahrestagung... ► Artikel lesen |